Kirou-Mauro Andrea M, Hird Amanda, Wong Jennifer, Sinclair Emily, Barnes Elizabeth A, Tsao May, Danjoux Cyril, Chow Edward
Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
J Pain Symptom Manage. 2009 Jan;37(1):77-84. doi: 10.1016/j.jpainsymman.2007.12.014. Epub 2008 May 27.
The primary objective of this study was to determine the prevalence of underdosage of analgesics for pain associated with bone metastases in outpatients referred to the Rapid Response Radiotherapy Program at the Odette Cancer Centre from 1999 to 2006. A prospective database containing data for all patients with bone metastases who were referred to the Rapid Response Radiotherapy Program for palliative radiotherapy from 1999 to 2006 was analyzed. The database included patient demographic information, including age at referral for radiation to the bone, gender, primary cancer site, and Karnofsky Performance Status; information on treatment-related factors, such as worst pain ratings and analgesic consumption in the past 24 hours (recorded as oral morphine equivalent doses); pain intensity ratings (none [rating=0], mild [rating=1-4], moderate [rating=5-6] or severe [rating=7-10]; and analgesic consumption (rated as none, nonopioids, weak opioids [e.g., codeine] and strong opioids [e.g., morphine and hydromorphone]). Patients who experienced moderate or severe pain and were prescribed no pain medication, nonopioids, or weak opioids were considered to be undermedicated. Between January 1999 and December 2006, 1,038 patients were included in the study database. Approximately 56% of patients were male and 44% were female. The median age was 68 years (range 28-95) and the median Karnofsky Performance Status was 70 (range 10-100). The percentages of undermedicated patients were 40% in 1999, 34% in 2000, 29% in 2001, 37% in 2003, 39% in 2004, 36% in 2005, and 48% in 2006. No appreciable decline was noted in the proportion of patients with moderate-to-severe pain who received no pain medication, nonopioids, or weak opioids during the study period. Despite the publication of pain management guidelines and the dissemination of data regarding the proportion of patients with bone metastases who are being prescribed inadequate analgesics, our findings suggest that a significant proportion of patients continue to be undermedicated.
本研究的主要目的是确定1999年至2006年转诊至奥德特癌症中心快速反应放射治疗项目的门诊患者中,因骨转移相关疼痛而使用镇痛药物剂量不足的发生率。分析了一个前瞻性数据库,该数据库包含1999年至2006年转诊至快速反应放射治疗项目接受姑息性放疗的所有骨转移患者的数据。该数据库包括患者人口统计学信息,如骨放疗转诊时的年龄、性别、原发癌部位和卡氏功能状态;治疗相关因素信息,如最严重疼痛评分和过去24小时的镇痛药物消耗量(记录为口服吗啡等效剂量);疼痛强度评分(无疼痛[评分为0]、轻度疼痛[评分为1 - 4]、中度疼痛[评分为5 - 6]或重度疼痛[评分为7 - 10])以及镇痛药物消耗量(分为无、非阿片类药物、弱阿片类药物[如可待因]和强阿片类药物[如吗啡和氢吗啡酮])。经历中度或重度疼痛且未开具任何止痛药物、非阿片类药物或弱阿片类药物的患者被视为药物治疗不足。1999年1月至2006年12月期间,1038名患者被纳入研究数据库。大约56%的患者为男性,44%为女性。年龄中位数为68岁(范围28 - 95岁),卡氏功能状态中位数为70(范围10 - 100)。药物治疗不足患者的比例在1999年为40%,2000年为34%,2001年为29%,2003年为37%,2004年为39%,2005年为36%,2006年为48%。在研究期间,接受不到止痛药物、非阿片类药物或弱阿片类药物治疗的中度至重度疼痛患者比例没有明显下降。尽管发布了疼痛管理指南并传播了关于骨转移患者镇痛药物处方不足比例的数据,但我们的研究结果表明,仍有相当比例的患者药物治疗不足。